SCHEMBL14927154

SCHEMBL14927154

CC(C)(C)C1Sc2ccccc2S1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
MAOA P21397 2/20 0.33
SLC6A2 P23975 2/20 0.33
CYP1A2 P05177 1/20 0.33
BCHE P06276 1/20 0.33
POLB P06746 1/20 0.33
CYP3A4 P08684 1/20 0.33
ADORA3 P0DMS8 1/20 0.33
GAA P10253 1/20 0.33
MAPT P10636 1/20 0.33
ALOX15 P16050 1/20 0.33
ALOX12 P18054 1/20 0.33
CNR1 P21554 1/20 0.33
ACHE P22303 1/20 0.33
PTGS1 P23219 1/20 0.33
HTR2C P28335 1/20 0.33
PTGS2 P35354 1/20 0.33
SNCA P37840 1/20 0.33
SLC6A3 Q01959 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2931874 0.69 MEN1 (0.36) MEN1KMT2AMAOASLC6A2CYP1A2
SCHEMBL6586181 0.68
SCHEMBL12264200 0.67 IDO1 (0.39) MEN1KMT2AMAOASLC6A2CYP1A2
SCHEMBL21215483 0.64 IDO1 (0.52) MEN1KMT2AMAOASLC6A2CYP1A2
SCHEMBL12213708 0.64
SCHEMBL13179482 0.64 BRD4 (0.32) MEN1KMT2ACYP1A2CYP3A4HTR2C
SCHEMBL24119411 0.64 GRM1 (0.41) MEN1KMT2AMAOASLC6A2CYP1A2
SCHEMBL7739423 0.63 IDO1 (0.36) MEN1KMT2AMAOASLC6A2CYP1A2
SCHEMBL7028419 0.63 IDO1 (0.36) MEN1KMT2AMAOASLC6A2CYP1A2
SCHEMBL7022756 0.63 IDO1 (0.36) MEN1KMT2AMAOASLC6A2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722900-B2 Process for cabazitaxel, and intermediates thereof SCINOPHARM TAIWAN, LTD. (TW) 2014-05-13 US disclosed
US-20130116444-A1 PROCESS FOR CABAZITAXEL, AND INTERMEDIATES THEREOF SCINOPHARM TAIWAN, LTD. (TW) 2013-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116444-A1 PROCESS FOR CABAZITAXEL, AND INTERMEDIATES THEREOF WEE1, XPO5, XPOT MEN1 2292/4885KMT2A 2018/4885MAOA 3679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.